Compare Freshworks Inc (FRSH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Recursion Pharmaceuticals Inc — how do they compare? Freshworks Inc trades at $13.75 (market cap $3.56B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Freshworks Inc is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FRSH | RXRX | |
|---|---|---|
Market Cap | $3.56B | $2.14B |
Volume | 9,066,454 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $13.92 | $6.79 |
52-Week Low | $6.88 | $2.84 |
Typical Hold Time | 39 Days | 22 Days |
Enterprise Value | $2.93B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.60, down 1.16% today, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company achieved its first GAAP profitability in Q2 2026 with revenue growth of 16% year-over-year, while maintaining impressive gross margins of 84.96%. Recent developments include FedRAMP certification progress and leadership in Gartner's ITSM Magic Quadrant.
The outlook remains positive with analyst consensus at $14.60 target (7.4% upside) and balanced buy/hold ratings. Key opportunities include AI monetization and enterprise expansion, while risks involve competitive SaaS pressures and execution on growth targets. The stock presents a compelling value proposition with improving profitability metrics.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
